Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1926 1
1927 1
1931 1
1933 1
1934 1
1939 1
1945 1
1946 3
1947 2
1948 1
1949 3
1951 1
1952 2
1953 1
1962 1
1971 1
1976 1
1979 1
1981 3
1984 1
1985 2
1986 3
1987 1
1988 1
1989 4
1990 3
1991 7
1992 10
1993 15
1994 10
1995 13
1996 10
1997 8
1998 8
1999 5
2000 6
2001 6
2002 2
2003 2
2004 5
2005 5
2006 2
2007 2
2008 14
2009 9
2010 10
2011 16
2012 19
2013 12
2014 11
2015 11
2016 12
2017 10
2018 10
2019 8
2020 13
2021 11
2022 8
2023 7
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

310 results

Results by year

Filters applied: . Clear all
Page 1
The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review.
Lauby A, Colomban O, Corbaux P, Peron J, Van Wagensveld L, Gertych W, Bakrin N, Descargues P, Lopez J, Kepenekian V, Glehen O, Philip CA, Devouassoux-Shisheboran M, Tod M, Freyer G, You B. Lauby A, et al. Among authors: tod m. Cancers (Basel). 2021 Dec 25;14(1):98. doi: 10.3390/cancers14010098. Cancers (Basel). 2021. PMID: 35008262 Free PMC article. Review.
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial.
You B, Robelin P, Tod M, Louvet C, Lotz JP, Abadie-Lacourtoisie S, Fabbro M, Desauw C, Bonichon-Lamichhane N, Kurtz JE, Follana P, Leheurteur M, Piano FD, Ferron G, De Rauglaudre G, Ray-Coquard I, Combe P, Chevalier-Place A, Joly F, Leary A, Pujade-Lauraine E, Freyer G, Colomban O. You B, et al. Among authors: tod m. Clin Cancer Res. 2020 Sep 1;26(17):4625-4632. doi: 10.1158/1078-0432.CCR-20-0054. Epub 2020 Mar 24. Clin Cancer Res. 2020. PMID: 32209570 Clinical Trial.
Aminoglycosides.
Lortholary O, Tod M, Cohen Y, Petitjean O. Lortholary O, et al. Among authors: tod m. Med Clin North Am. 1995 Jul;79(4):761-87. doi: 10.1016/s0025-7125(16)30038-4. Med Clin North Am. 1995. PMID: 7791422 Review.
Azithromycin for COVID-19: More Than Just an Antimicrobial?
Bleyzac N, Goutelle S, Bourguignon L, Tod M. Bleyzac N, et al. Among authors: tod m. Clin Drug Investig. 2020 Aug;40(8):683-686. doi: 10.1007/s40261-020-00933-3. Clin Drug Investig. 2020. PMID: 32533455 Free PMC article. No abstract available.
Antienterococcal antibiotics.
Lefort A, Mainardi JL, Tod M, Lortholary O. Lefort A, et al. Among authors: tod m. Med Clin North Am. 2000 Nov;84(6):1471-95. doi: 10.1016/s0025-7125(05)70298-4. Med Clin North Am. 2000. PMID: 11155853 Review.
Pharmacodynamic models for discrete data.
Paule I, Girard P, Freyer G, Tod M. Paule I, et al. Among authors: tod m. Clin Pharmacokinet. 2012 Dec;51(12):767-86. doi: 10.1007/s40262-012-0014-9. Clin Pharmacokinet. 2012. PMID: 23179578 Review.
Clinical pharmacokinetics of diacerein.
Nicolas P, Tod M, Padoin C, Petitjean O. Nicolas P, et al. Among authors: tod m. Clin Pharmacokinet. 1998 Nov;35(5):347-59. doi: 10.2165/00003088-199835050-00002. Clin Pharmacokinet. 1998. PMID: 9839088 Review.
310 results